175 related articles for article (PubMed ID: 33997104)
1. Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair.
Bouredji Z; Hamoudi D; Marcadet L; Argaw A; Frenette J
Mol Ther Methods Clin Dev; 2021 Jun; 21():559-573. PubMed ID: 33997104
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin and β
Dufresne SS; Boulanger-Piette A; Frenette J
Am J Pathol; 2017 Mar; 187(3):498-504. PubMed ID: 28041995
[TBL] [Abstract][Full Text] [Related]
5. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
6. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
7. TNF Receptor: Fc Fusion Protein Downregulates RANKL/OPG Ratio by Inhibiting CXCL16/CXCR6 in Active Ankylosing Spondylitis.
Zhang P; Zhou S; Chen Z; Tian Y; Wang Q; Li H; Zhang T; Guo Q; Wang M; Guo C
Curr Pharm Biotechnol; 2021; 22(2):305-316. PubMed ID: 32116188
[TBL] [Abstract][Full Text] [Related]
8. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
9. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Miller RE; Branstetter D; Armstrong A; Kennedy B; Jones J; Cowan L; Bussiere J; Dougall WC
J Immunol; 2007 Jul; 179(1):266-74. PubMed ID: 17579046
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
Hofbauer LC; Neubauer A; Heufelder AE
Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.
Lloyd SA; Morony SE; Ferguson VL; Simske SJ; Stodieck LS; Warmington KS; Livingston EW; Lacey DL; Kostenuik PJ; Bateman TA
Bone; 2015 Dec; 81():562-572. PubMed ID: 26318907
[TBL] [Abstract][Full Text] [Related]
13. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
14. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
15. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
[TBL] [Abstract][Full Text] [Related]
16. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis.
Kim HK; Morgan-Bagley S; Kostenuik P
J Bone Miner Res; 2006 Dec; 21(12):1946-54. PubMed ID: 17002576
[TBL] [Abstract][Full Text] [Related]
17. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
18. [Electroacupuncture Intervention Improves Cartilage Degeneration and Subchondral Bone Osteoporosis of Knee-joint Possibly by Adjusting OPG/RANK/RANKL Signaling in Ovariectomized Rats].
Sun GH; Liao Y; Liao Y; Ni ZY; Li N; Zhong PR; Li XH; Zhou J
Zhen Ci Yan Jiu; 2018 Dec; 43(12):781-7. PubMed ID: 30585456
[TBL] [Abstract][Full Text] [Related]
19. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.
Jin Q; Cirelli JA; Park CH; Sugai JV; Taba M; Kostenuik PJ; Giannobile WV
J Periodontol; 2007 Jul; 78(7):1300-8. PubMed ID: 17608585
[TBL] [Abstract][Full Text] [Related]
20. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
